MYELOPROLIFERATIVE DISORDERS RESEARCH CONSORTIUM
Geisinger has recently joined the Myeloproliferative Disorders Research Consortium (MPD-RC). MPD-RC investigators hail from approximately 28 institutions throughout the U.S. and Europe and share a commitment to enhancing research on myeloproliferative disorders, realizing that clinical and basic research in this area cannot flourish in isolation.
Funded by the National Cancer Institute and the Centers for Disease Control and Prevention, the MPD-RC focuses on the Philadelphia (Ph) chromosome negative MPDs (including polycythemia vera (P. vera) and idiopathic myelofibrosis to coordinate and facilitate basic and clinical research dealing with the cellular and genetic basis of the Ph-negative MPD. The Consortium’s efforts include conducting clinical trials, as well as developing a bank of patient samples to allow researchers to identify specific biomarkers that will be useful as indicators of therapeutic response and/or risk reduction.
The MPD-RC’s mission “is to achieve an understanding of these disorders’ biological bases and to develop curative strategies...” As a member of the Consortium, Geisinger has the opportunity to conduct Consortium studies and access the MPD-RC Research Tissue Bank which collects and stores tissue specimens from MPD patients. These specimens are used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of MPDs